Monica Akre, PhD
My work focusses on the use of cell line expression data and corresponding drug responsiveness with the goal of identifying predictive expression profiles that will better direct use of effective therapeutics and avoid ineffective options.
Samuel Callisto, PhD
Samuel was a PhD Candidate in the Experimental and Clinical Pharmacology department. During his time in the program Samuel pursued various avenues of research related to precision medicine in neuropharmacology with a focus on anti-seizure drugs. Projects included the effect of patient demographics on likelihood of experiencing side effects from topiramate, the pharmacogenomic underpinnings of lamotrigine clearance changes during pregnancy, and clinical applications of pharmacogenomics to epilepsy treatment.
Elise Durgin, PharmD
Dr. Elise Durgin was the first PGY2 resident in Clinical Pharmacogenomics at Children’s Minnesota.Her residency focused on developing expert skills providing clinical pharmacogenomic consultations to health-care providers and patients/families. In addition she gained experience developing the educational and EHR resources necessary to implement new clinical services by participating in ongoing pharmacogenomics program expansion at Children’s Minnesota. Dr. Durgin's research evaluated the association of CYP2D6 genotype on treatment outcomes with atomoxetine in patients with ADHD treated at Children's Minnesota. This project laid the foundation for a prospective evaluation of the implementation of recently published Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2D6 Genotype and atomoxetine.
Seenae Eum, PharmD
Medications with high anticholinergic activity have adverse effects on neuropsychological performance. During her time with PUMA, Dr. Eum word on quantifying neuropsychological performance relationships with anticholinergic burden and genetic factors in patients with psychotic disorders, first degree relatives, and controls with the goal of identifying key genetic variants associated with anticholinergic effects on cognitive phenotypes.
Taylor Harding, PhD
Using pre-clinical modeling to identify transcriptomic signatures that accurately predict drug resistance in multiple myeloma. Additionally, we are testing new chemotherapeutic approaches to target unique features of the myeloma epigenome and improve the efficacy of current therapies.
Megan Hundertmark, PharmD
Megan Hundertmark was a fourth-year pharmacy student on the Duluth campus interested in advancing pharmacy practice to ensure that patients are able to access and afford medications best suited for them. For her research emphasis, she hasworked with Jacob Brown, PharmD, MS to research the implementation of pharmacogenomic testing. She published a survey, Primary Care Clinicians Attitudes and Knowledge of Pharmacogenetics in a Large, Multi-state, Healthcare System, which showed that primary care clinicians think pharmacogenomics is important for practice and that pharmacists are the best suited to take on the task. She worked on another survey that was administered to pharmacists to determine if post-graduate education and board certification has an impact on a pharmacist’s opinion of pharmacogenomics.
Gregory Laffen, PharmD
Pharmacogenomic determinants of the serum uric acid lowering effects of the drug fenofibrate. We aim to determine if there are genetic markers that can be used as predictors of both drug response and serum uric acid levels that can be used to help guide clinical decision making in order to improve treatment of gout and help ease the burden of comorbid cardiovascular disease.
Lauren Lemke, PharmD
Lauren graduated from the University of Minnesota PharmD program in 2020 and is now a PGY1 resident at Essentia Healthcare in Duluth, MN. Originally from small-town Wisconsin, her research was in the lab of Stephanie Huang and centered around identifying and validating biomarkers for anticancer drug resistance and sensitivity. She is interested in both somatic and germline pharmacogenomics as well as their implementation into clinical practice.
During my time with PUMA, my research project involved studying Multiple Myeloma and the long-term effects of an epigenetic modifying drug called EPZ-6438 on human myeloma cell lines. This drug is an EZH2 inhibitor; EZH2 is a protein complex in the cell attributed with oncogenic activity in Multiple Myeloma. We concluded EPZ-6438 to be a potential novel therapy in treating Multiple Myeloma.
Malek Okour, PhD
Pharmacokinetics and pharmacodynamics analysis of mycophenolic acid (MPA) in kidney transplant recipients. We aim into individualizing therapy while keeping in mind exposure relation to acute rejection and side effects.
Christopher Olson, PharmD
The current lifetime prevalence of psychotic disorders is approximately 4.1% with non-response to standard treatments being in the range of 40-50%. This reveals a need for improvements in current treatment practices and the use of pharmacogenomics can help to improve the precision of individual patient treatments; therefore, we are aiming to analyze various dopamine receptor and transporter single nucleotide polymorphisms (SNPs) in relation to participant’s antipsychotic dosing.
Rebecca Pulk, PharmD
Tacrolimus is a calcineurin inhibitor immunosuppressant that widely used in kidney transplant. I am working to improve our ability to select an optimized tacrolimus dose for kidney transplant patients based on their individual clinical and genetic factors to decrease time to optimal coverage and improve clinical outcomes.
Youssef Roman, PharmD, PhD
The contribution of genetic polymorphisms in select genes responsible for uric acid disposition and the drugs used to treat hyperuricemia and gout. My ultimate goal is to identify key genetic variants to be used for guided drug selection to optimally manage patients with gout, hyperuricemia, and their associated comorbidities.
Kinjal Sanghavi, PhD
Improving immunosuppressive therapy in transplantation using population pharmacokinetic and pharmacogenetic approach. These approaches were used to optimize dosing for tacrolimus (for kidney transplant recipients) and fludarabine (for hematopoietic stem cell transplant recipients).
Aileen Scheibner, PharmD
Fludarabine and cyclophosphamide are chemotherapeutics used in hematopoietic cell transplant (HCT) preparative regimens for their anticancer and immunosuppressive properties. We are investigating the relationship between fludarabine and cyclophosphamide pharmacokinetics, single nucleotide polymorphisms (SNPs), and non-relapse mortality, neutrophil engraftment, overall survival and acute graft-versus-host disease in patients undergoing allogeneic nonmyeloablative HCT. Understanding the relationships between target SNPs, pharmacokinetics, and clinical outcomes will facilitate the development of a personalized approach to HCT preparative regimens that improves safety and overall survival while minimizing the risk of acute graft-versus-host disease.
Stephan Seibert, PharmD
Tacrolimus is the cornerstone immunosuppressive agent after kidney transplantation, but its high pharmacokinetic variability is a well-known problem which contributes to adverse effects and poor outcomes. We are investigating the associations between intra-patient tacrolimus pharmacokinetic variability, CYP3A5 loss of function alleles, and acute rejection in a large cohort of African American and European American kidney transplant recipients.
MicroRNAs regulate gene expression, participate in normal neuro developmental and physiological processes, and have recently been implicated in the pathogenesis of several psychiatric disorders. My project aims to examine the relationship between microRNA genetic variants and antipsychotic treatment response outcomes in patients with psychosis. We hope that this project will enhance our understanding of miRNAs as therapeutic biomarkers in psychiatric disorders.